Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Active Not Recruiting
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: * Cannot be removed by an operation * Has spread to other parts of the body
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Ironwood Cancer & Research Centers - Chandler II, Chandler, Arizona +207 locations
Conditions: Breast Cancer
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
Terminated
The purpose of this study was to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel and ramucirumab in patients with gastric adenocarcinoma (GAC) i.e. with human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring fibroblast growth factor receptor 2 (FGFR2) genetic aberrations (GA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: AdventHealth Cancer Institute, Orlando, Florida +80 locations
Conditions: Gastric Adenocarcinoma
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Completed
This Phase 3, multicenter, randomized, double-blind, placebo controlled study is designed to evaluate the efficacy and safety of atezolizumab (MPDL3280A, an anti-programmed death-ligand 1 \[PD-L1\] antibody) administered in combination with paclitaxel compared with placebo in combination with paclitaxel in participants with previously untreated, inoperable locally advanced or metastatic, centrally confirmed TNBC. Participants will be randomized in a 2:1 ratio to receive atezolizumab or placebo p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Stanford Cancer Center, Stanford, California +160 locations
Conditions: Triple-Negative Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
Completed
This randomized, 3-arm, multicenter, phase III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) with pertuzumab or trastuzumab emtansine (T-DM1) with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab (Herceptin) plus taxane (docetaxel or paclitaxel) in participants with HER2-positive progressive or recurrent locally advanced or previously untreated metastatic breast cancer. Participants will be randomized to 1 of 3 treatment arms (Arms... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: Uni of Arkansas For Medical Sciences; Arkansas Cancer Research Center, Little Rock, Arkansas +256 locations
Conditions: Breast Cancer
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Completed
This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: USA Mitchell Cancer Institute, Mobile, Alabama +181 locations
Conditions: Triple-Negative Breast Cancer
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Completed
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) breast adenocarcinoma who are not suitable for endocrine therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: UCSD Moores Cancer Center, La Jolla, California +175 locations
Conditions: Breast Cancer
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Terminated
This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +59 locations
Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
Recruiting
This study is comparing two combinations of chemotherapy treatments in patients with metastatic pancreatic cancer. Half the participants will receive FOLFOX-A and the other half will receive AG. Treatment will continue until progression or patient/clinican decision or intolerable toxicity.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
02/07/2024
Locations: Aberdeen Royal Infirmary, Aberdeen, Not set +29 locations
Conditions: Neoplasms Pancreatic
European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)
Terminated
To evaluate the procedural safety and to identify and characterize therapeutic and functional endpoint assessments in subjects with documented critical limb ischemia who received treatment with the Cotavance Paclitaxel-Coated Balloon vs. those who received POBA only.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Medical University, Graz, Not set +5 locations
Conditions: PAD, Infrapopliteal Lesions
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
Active Not Recruiting
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast cancer.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
01/23/2024
Locations: Cliniques Universitaires Saint-Luc, Brussels, Not set +72 locations
Conditions: Breast Cancer Stage II, Breast Cancer Stage III
Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Completed
The trial will compare the drugs olaparib and cediranib with standard chemotherapy in platinum resistant ovarian cancer. Patients will be randomised to one of three treatment groups: olaparib only, olaparib and cediranib and the control group paclitaxel. The aim is to compare efficacy of the 3 treatments and also how well each treatment is tolerated including the participants quality of life.
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
01/22/2024
Locations: Belfast City Hospital, Belfast, County Antrim +13 locations
Conditions: Ovarian Cancer
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Completed
The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gastrointestinal and genitourinary tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Clearview Cancer Institute /ID# 1128-0965, Huntsville, Alabama +64 locations
Conditions: Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma